These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Ghazali A; Fardellone P; Pruna A; Atik A; Achard JM; Oprisiu R; Brazier M; Remond A; Morinière P; Garabedian M; Eastwood J; Fournier A Kidney Int; 1999 Jun; 55(6):2169-77. PubMed ID: 10354266 [TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
4. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy. Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547 [TBL] [Abstract][Full Text] [Related]
5. Are low plasma levels of 25-(OH)vitamin D a major risk factor for hyperparathyroidism independent of calcitriol in renal transplant patients? Lomonte C; Antonelli M; Vernaglione L; Cazzato F; Casucci F; Chimienti D; Bruno A; Cocola S; Verrelli EA; Basile C J Nephrol; 2005; 18(1):96-101. PubMed ID: 15772930 [TBL] [Abstract][Full Text] [Related]
6. Renal ostodystrophy during the developing stage of maintenance dialysis in Transylvania. Early development of periarticular calcifications and beta 2 microglobulin amyloidosis in spite of a relatively good prevention of secondary hyperparathyroidism. Oprisiu R; Bolosiu H; Boca I; Theodoru C; Elefterescu R; Brazier M; el Esper I; Leflon P; Ledeme C; Fournier A; Heinze V Ann Med Interne (Paris); 1998 Mar; 149(2):67-75. PubMed ID: 11490527 [TBL] [Abstract][Full Text] [Related]
7. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA; Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602 [TBL] [Abstract][Full Text] [Related]
8. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210 [TBL] [Abstract][Full Text] [Related]
9. The impact of chronic inflammation on bone turnover in hemodialysis patients. Eleftheriadis T; Kartsios C; Antoniadi G; Kazila P; Dimitriadou M; Sotiriadou E; Koltsida M; Golfinopoulos S; Liakopoulos V; Christopoulou-Apostolaki M Ren Fail; 2008; 30(4):431-7. PubMed ID: 18569918 [TBL] [Abstract][Full Text] [Related]
10. 7-84 parathyroid hormone fragments are proportionally increased with the severity of uremic hyperparathyroidism. Chang JM; Lin SP; Kuo HT; Tsai JC; Tomino Y; Lai YH; Chen HC Clin Nephrol; 2005 May; 63(5):351-5. PubMed ID: 15909594 [TBL] [Abstract][Full Text] [Related]
12. Effect of CAPD and hemodialysis on parathyroid function. Malberti F; Corradi B; Imbasciati E Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912 [TBL] [Abstract][Full Text] [Related]
13. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Anderson JL; Vanwoerkom RC; Horne BD; Bair TL; May HT; Lappé DL; Muhlestein JB Am Heart J; 2011 Aug; 162(2):331-339.e2. PubMed ID: 21835295 [TBL] [Abstract][Full Text] [Related]
14. Effect of vitamin C on parathyroid hormone in hemodialysis patients with mild to moderate secondary hyperparathyroidism. Sanadgol H; Bayani M; Mohammadi M; Bayani B; Mashhadi MA Iran J Kidney Dis; 2011 Nov; 5(6):410-5. PubMed ID: 22057074 [TBL] [Abstract][Full Text] [Related]
15. Secondary hyperparathyroidism among Nigerians with chronic kidney disease. Gimba ZM; Abene EE; Agbaji OOO; Agaba EI Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. Joy MS; Karagiannis PC; Peyerl FW J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511 [TBL] [Abstract][Full Text] [Related]
18. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism. Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764 [TBL] [Abstract][Full Text] [Related]
19. [Renal osteodystrophy (3); its treatment in dialysis patients]. Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385 [TBL] [Abstract][Full Text] [Related]
20. [Prevalence of secondary hyperparathyroidism (SHPT) and causal factors in adult population in Reykjavík area]. Karlsson SL; Indridason OS; Franzson L; Sigurdsson G Laeknabladid; 2005 Feb; 91(2):161-9. PubMed ID: 16155312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]